Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Biocompatible and long-acting polyphosphate inhibitors for the diagnosis and treatment of thrombosis and thromboembolism.

Biomaterials advances·2026
Same author

Synergistic Thrombolysis-Antiplatelet Therapy of Engineered tPA Variant citPA5 and Tirofiban in a Mouse Stroke Model.

Thrombosis and haemostasis·2026
Same author

Corrigendum "Anticancer effects of salidroside on ovarian cancer carcinogenesis and molecular mechanism in mice" [Biomed. Pharmacother. 198 (2026) 119250].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Internal insertion in albumin improves fusion-protein integrity while maintaining bioactivity and FcRn interaction.

International journal of biological macromolecules·2026
Same author

Kisspeptin-10 Promotes Hormone Secretion, Ovarian Follicles Development and Fecundity via PI3K/AKT/ERK Signal Pathway in Mice.

Molecular reproduction and development·2026
Same author

Anticancer effects of salidroside on ovarian cancer carcinogenesis and molecular mechanism in mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

相关实验视频

Updated: Jun 29, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K

一种低出血风险的血栓消毒剂:citPA5

Shanli Chen1, Sudan Fang1, Yang Zhou1

  • 1College of Chemistry, Fuzhou University, No.2 Wulongjiang North Avenue, Fuzhou 350108, China.

Cardiovascular research
|March 28, 2024
PubMed
概括

一种新型的血栓溶解剂,citPA5,表现出强大的凝块溶解能力,与阿尔特相比,显著降低出血风险. 这种增强的安全性允许在医院前进行潜在的中风治疗,改善患者的治疗结果.

关键词:
增强了tPA的功效.缺血性中风 缺血性中风低出血风险 低出血风险血栓溶解药物治疗的方法

更多相关视频

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

21.9K

相关实验视频

Last Updated: Jun 29, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

21.9K

科学领域:

  • 生物化学 生化学
  • 药理学 药理学是指药理学的学科.
  • 心血管研究研究心血管研究

背景情况:

  • 阿尔特普拉斯是用于中风的标准血栓缓解剂,但具有出血风险,需要在治疗前进行查.
  • 当前的血栓解压疗法在给药前需要区分缺血性和出血性中风.

研究的目的:

  • 开发和表征一种新型血栓溶解剂,citPA5,具有改善的安全性和降低出血倾向.
  • 在临床前中风模型中评估citPA5的疗效和安全性.

主要方法:

  • 工程重组组织等离子体激活剂 (rtPA) 具有点突变来产生citPA5,抑制纤维素独立活性.
  • 评估了纤维解质活性和对塑原激活剂抑制剂-1 (PAI-1) 的耐药性.
  • 进行了安全评估,包括血栓造影,小鼠尾部出血试验和小鼠脑内出血模型. 在动脉栓塞诱导的中风模型中评估了疗效.

主要成果:

  • CitPA5显著增强了纤维解酶活性 (15.8倍的kcat/Km增加) 和对PAI-1的抗性.
  • 安全性评估显示,与阿尔特相比,citPA5不会引起全身出血或恶化脑内出血.
  • 在中风模型中,CitPA5有效地改善了大脑血液流动,并减少了心脏病发作体积.

结论:

  • CitPA5提供强大的血栓溶解与低出血风险,表明在医院前设置中早期中风治疗的潜力.
  • 这种新型药物可以实现更快的中风干预,而不需要立即进行中风类型分类.
  • 对citPA5的开发策略可能为新一代更安全,更具特异性的纤维溶解药物铺平道路.